Realizing AI’s Potential in Drug Discovery: Join our CEO, Colin Hill on the Top of Mind for Life Sciences Summit 2023
We are excited to announce that Aitia will be participating in the highly anticipated Top of Mind for Life Sciences Summit 2023 conference. Our CEO, Colin Hill, will be a featured speaker on an insightful panel discussion entitled “Realizing AI’s Potential in Drug Discovery” moderated by Rob Hartman, Senior Director from UPMC Enterprises. During the […]
MDS Poster | Gemini Digital Twins Identified Neuro-Common and Disease-Specific Drivers of Blood NfL Change Rate
X.Shen, S.Sathe, L.Sun, P.Ashrap, K.Johnson, S.Sukhram, S.Reddy, S-Y.Shin, J.Latourelle, C.Sampaio
Exploring the Frontiers of AI-driven Drug Discovery: A Conversation with Aitia on The Long Run Podcast
Colin Hill joined Luke Timmerman on “The Long Run” podcast, to explore Aitia’s journey and its impact on the realm of drug discovery. In this episode, Colin and Luke delve into the genesis of Aitia. From its humble beginnings to its current status as a pioneering in the industry. 🎧 If you would like to […]
Servier and Aitia Mobilize AI and Digital Twins to Treat Pancreatic Cancer
The French pharmaceutical group Servier and Aitia announced on May 17th a multi-year partnership agreement for the discovery and simulation of drugs in pancreatic cancer. It is based on the combination of Servier’s expertise in preclinical trials with Aitia’s technology, which is based on artificial intelligence and Gemini Digital Twins. Read more on the latest […]
Colin Hill Keynote at Servier Paris-Saclay R&D Institute in France
On July 20th, we had the privilege to visit the cutting-edge Servier Paris-Saclay R&D Institute in France, where our CEO, Colin Hill delivered a keynote titled: “Why AI and Digital Twins will Drive the Discovery and Development of the Next Generation of Breakthrough Drugs“. The open conference was a remarkable display of Servier’s dedication to foster a collaborative […]
AAIC Poster | Alzheimer’s Disease Mechanistic Pathways were Discovered through in silico Experiments in Causal AI based Digital Twins
Apoorva Bharthur Sanjay, Deepanshi Shokeen, Xinyu Shen, So-Youn Shin and Jeanne Latourelle
Colin Hill Weighs in on the Future of Drug Discovery on the Patients Rising Podcast
Our CEO, Colin Hill was a special guest on the Patients Rising Podcast. In this week’s episode, Colin passionately shared his beliefs and vision for the future of medical research, highlighting the transformative potential of AI-powered clinical trials and the revolutionary power of Digital Twins. Tune in to the podcast episode now and discover how Digital […]
Open to Debate: Is the FDA’s Caution Hazardous to your Health?
During the COVID-19 pandemic, the Atlantic lambasted the US Food and Drug Administration for moving too slowly to approve vaccines with the provocative headline “The Death Toll of Delay.” Not long before, National Public Radio had run a piece titled “One-Third of New Drugs Had Safety Problems After FDA Approval.” As the agency tries to […]
Alzheimer’s Disease Mechanistic Pathways Discovered through Aitia’s Digital Twins and in silico Experiments in Causal AI to be Presented at AAIC 2023
We are delighted to announce that Aitia will be at the upcoming Alzheimer’s Association International Conference (AAIC) being held from July 16-20 in Amsterdam, Netherlands. We will be presenting a poster focused on identification of gene pathways with direct causal relationships to Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on Bayesian […]
Join our CEO, Colin Hill on the Aspen Ideas: Health Panel
We are thrilled to announce that Aitia will be participating in the highly anticipated Aspen Ideas: Health conference. Our CEO, Colin Hill, will be taking the stage on a thought-provoking panel titled “Open to Debate: Is the FDA too Cautious?” alongside distinguished panelist Peter Lurie, President and Executive Director of the Center for Science in […]